2022 RESEARCH AND CLINICAL CARE MEETING

Diminished motor neuron activity driven by abnormal astrocytic GLAST glutamate transporter in spinal muscular atrophy is not fully restored after lentiviral SMN delivery

> Emily Welby, Ph.D. Postdoctoral Fellow Cell Biology, Neurobiology and Anatomy (Ebert lab) Medical College of Wisconsin



Contribution of other cell types to SMA motor neuron dysfunction?



Astrocyte neuron-communication

- Astrocytes are key regulators of synapse formation and function
 - Excitatory
 - Glutamatergic
- Secreted factors into the synaptic cleft
 - Thrombospondin
 - Tenascin
 - SPARC
 - Gliotransmitters
 - Glutamate
 - ATP
 - D-serine
 - microRNAs



- Cell surface proteins
 - Cell adhesion molecules
 - Neuroligin
 - Neurexin
 - Cadherins
 - Ephrins
 - Protocadherins
 - Ion channels
 - K_{ir}4.1, Na+ K+ ATPases
 - Neurotransmitter receptors
 - Metabotropic glutamate receptors (mGluR, P2Y2)
 - Neurotransmitter transporters
 - Glutamate (GLT-1 and GLAST)



SMA astrocyte defects correlated to the synapse

- Mouse studies
 - Synapse formation and activity is significantly reduced in SMA astrocyte motor neuron direct contact co-cultures (Zhou et al., 2016)
 - Potential candidate: Ephrin B2 reduction (axon guidance and synapse development)
 - Reduced inward rectifier potassium channel K_{ir}4.1 and glutamate transporter EAAT1 in SMA mouse spinal cords. Leads to reduced potassium and glutamate uptake in mouse SMN siRNA astrocytes (Leo et al., 2022)
- Human induced pluripotent stem cell (iPSC)-derived cultures
 - Astrocyte-mediated miR-146a may target extracellular matrix proteins within perineuronal nets to decrease motor neuron activity (Welby et al., 2021)
 - Human iPSC-derived astrocytes show increased basal calcium levels and minimal calcium response through ATP stimulation despite presence of purinergic receptors (McGivern et al., 2013)



SMA astrocytes diminish motor neuron activity (evoked)



SMA astrocytes diminish motor neuron activity (evoked)



Microelectrode array (Axion Biosystems)

cure



- SMA patient iPSC-derived astrocytes diminish motor neuron activity in direct contact co-cultures
- Healthy derived astrocytes normalize abnormal burst activity
 in patient motor neuron cultures

Astrocyte cell surface protein candidates (RNA seq data)



10

20

50

100

Synaptic integrity

Glutamate regulation

- 1221 upregulated
- 1734 downregulated

-log10 of adjusted p-value 2022 RESEARCH AND CLINICAL CARE MEETING

Disrupted astrocytic glutamate neuromodulation contributes towards central afferent synapse dysfunction?



Hypothesis

SMA astrocytes contribute to motor neuron dysfunction due to the lack important synaptic-related cell surface glycoproteins

Strategy

- 1. Differences in cell surface transcripts/proteins between healthy and SMA astrocytes (RNA seq/cell surface capture data)
- 2. Candidate of interest validation
- 3. Impact on motor neurons (microelectrode array approach)
- 4. Mechanism: SMN dependent/independent?



Significant reduction of GLAST in SMA patient-derived astrocytes



2022 RESEARCH AND CLINICAL CARE MEETING

cure

Astrocyte specific glutamate transporters: GLAST and GLT-1



- Responsible for at least 80% of synaptic glutamate clearance and recycling
- Uptake of glutamate against concentration gradient
 - Na+ dependent glutamate uptake
 - Similar glutamate affinity for both transporters

Regulated by:

- Neurons (direct contact and secreted factors)
- Synaptic activity (e.g. glutamate)
 - Coupled to Na+/K+ ATPases and mGluR
- Extensive stimuli that affect trafficking of EAAT to and from intracellular pools and lipid rafts (caveolae)

CURE 2022 RESEARCH AND CLINICAL CARE MEETING

Specific GLAST inhibition fails to decrease intracellular glutamate in SMA patient-derived astrocytes





cure

Specific GLT-1 inhibition decreases intracellular glutamate in healthy and SMA patient-derived astrocytes



2022 RESEARCH AND CLINICAL CARE MEETING

cure

GLAST inhibition mimics diminished neuron activity from SMA astrocyte co-cultures







GLAST inhibition mimics diminished neuron activity from SMA astrocyte co-cultures



2022 RESEARCH AND CLINICAL CARE MEETING

cure

Lentiviral mediated delivery of SMN into SMA patient astrocytes



CURE 2022 RESEARCH AND CLINICAL CARE MEETING

Partial restoration of GLAST phenotype after SMN re-expression





Partial restoration of GLAST phenotype after SMN re-expression



2022 RESEARCH AND CLINICAL CARE MEETING

cure

Abnormally upregulated caveolin-1 levels in patient astrocytes



Caveolin-1 (CAV-1)

- Scaffold protein required for the formation of caveolae (lipid raft endocytosis)
- Directly interacts with SMN to facilitate local protein translation (Gabanella et al., 2016)
- DJ-1 deficiency impairs caveolin-1 levels, lipid raft endocytosis and glutamate transporter expression and glutamate uptake in Parkinson's disease astrocytes (Kim et al., 2016)



Partial restoration of CAV-1 phenotype after SMN re-expression



CUIE SMA

Partial restoration of CAV-1 phenotype after SMN re-expression





Minimal MN activity in SMN:FLAG/GFP patient-derived astrocytes



cure



Healthy MN SMN:FLAG astrocytes



SMA MN SMA astrocytes



Healthy MN SMN:GFP astrocytes



Conclusions and future directions



- SMA patient-derived astrocytes
 - directly impede motor neuron activity
 - reduced GLAST levels
 - Increased CAV-1 levels
- Disease mechanism involving SMN-CAV-1 regulation of GLAST
 - Impaired local protein translation and turnover of plasma membrane protein-> disrupted glutamate neurotransmission?

SMN-dependent/associated mechanism?

- Further SMN modulation needed?
- Reactivity-> insensitive to SMN restoration?

CURE 2022 RESEARCH AND CLINICAL CARE MEETING

Conclusions and future directions



- SMA patient-derived astrocytes
 - directly impede motor neuron activity
 - reduced GLAST levels
 - Increased CAV-1 levels
- Disease mechanism involving SMN-CAV-1 regulation of GLAST
 - Impaired local protein translation and turnover of plasma membrane protein-> disrupted glutamate neurotransmission?

SMN-dependent/associated mechanism?

- Further SMN modulation needed?
- Reactivity-> insensitive to SMN restoration?
- Other astrocytic defects linked glutamate neurotransmission?
 - Related to GLAST regulation (mGluR, Na+/K+ ATPases, calcium signaling)
 - Increased glutamate levels
 - Disrupted glutamate-glutamine cycle
 - Impaired synaptogenesis (ephrins)

CURE 2022 RESEARCH AND CLINICAL CARE MEETING

Microscale cell surface capture mass spectrometry: enrichment of synapse-related glycoproteins in healthy-derived astrocytes



Acknowledgments

Ebert laboratory, MCW

- Allison Ebert, PhD
- John Whitinger IV, MD (Child Neurology resident)
- Ben O'Brien Hokanson (graduate student)
- Reilly Allison (graduate student)
- Jake Adelman (graduate student)



Audrey Lewis Young Investigator Award (2020)



cure

National Institute of Neurological Disorders and Stroke

Collaborations

uCSC mass spectrometry

- Rebekah Gundry, PhD
- Linda Luecke Berg, PhD
- SMN:GFP/FLAG plasmids
- Xue Jun Li, PhD (University of Illinois-Chicago)
- Christian Lorson, PhD (University of Missouri)
 Lentivirus production

Lentivirus production

- Viral Vector Core Facility (MCW/ Versiti BRI)
 Microelectrode array system
- Cardiovascular Center (MCW)
- mRNA sequencing
- Sridhar Rao, MD, PhD (MCW/Versiti BRI)

Human samples

Human iPSC lines (2 healthy individuals and 3 SMA patients)

Human spinal cord tissue

- University of Maryland Brain and Tissue Bank
- NIH NeuroBioBank



Questions/Info

Emily Welby ewelby@mcw.edu

